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Abstract
Complement factor H (CFH) regulates complement activation in host tissues through its
recognition of polyanions, which mediate CFH binding to host cell surfaces and extracellular
matrix, promoting the deactivation of deposited C3b. These polyanions include heparan sulfate
(HS), a glycosaminoglycan (GAG) with a highly diverse range of structures, for which two
regions of CFH (referred to as CCP6-8 and CCP19-20) have been implicated in HS binding.
Mutations/polymorphisms within these GAG-binding sites have been associated with age-related
macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS). Here we
demonstrate that CFH has tissue-specific binding properties, mediated through its two HS-binding
regions. Our data shows that the CCP6-8 region of CFH binds more strongly to heparin (a highly
sulfated form of HS) than CCPs19-20 and that their sulfate specificities are different. Furthermore,
the HS-binding site in CCPs6-8, which is affected by the AMD-associated Y402H polymorphism,
plays the principle role in host tissue recognition in the human eye, whilst the CCP19-20 region
makes the major contribution to the binding of CFH in the human kidney. This helps provide a
biochemical explanation for the genetic basis of tissue-specific diseases such as AMD and aHUS,
and leads to a better understanding of the pathogenic mechanisms for these diseases of
complement dysregulation.
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Introduction
Complement factor H (CFH), a 155-kDa plasma protein, is the main regulator of the
alternative pathway of complement, a key component of the innate immune response. The
presence of CFH in tissues (where it is bound to host surfaces) leads to the breakdown of
any deposited C3b that would otherwise result in complement amplification (1). While other
proteins exert regulatory activity on host cell surfaces, i.e. CD35, CD46 and CD55 (2), CFH
is the only alternative pathway regulator to confer protection to extracellular matrix (ECM)
structures such as basement membranes (3,4). Impaired CFH function is a major
contributing factor in the kidney disease atypical hemolytic uremic syndrome (aHUS) (5,6)
and age-related macular degeneration (AMD) (7-13), which is the leading cause of blindness
in the western world (14). In AMD, complement dysregulation is associated with drusen
formation between the retinal pigment epithelium (RPE) and a multi-laminar ECM called
Bruch’s membrane (11), resulting in the destruction of the macula and consequent loss of
central vision.
CFH recognizes host surfaces through its interactions with certain polyanions, such as the
glycosaminoglycan (GAG) chains of proteoglycans that are present on all cells and in the
ECM of host tissues (12,15,16); GAGs are long, un-branched, polysaccharides composed of
disaccharide repeats that show a huge diversity in sequence based largely on variable
sulfation patterns (see Supplemental Fig. 1). CFH is comprised of twenty complement
control protein (CCP) domains (17) (also referred to as short consensus repeats or SCRs),
containing two GAG-binding regions corresponding to CCPs6-8 and CCPs19-20 (18-25).
Importantly, mutations and polymorphisms in these GAG-binding regions of CFH have
been associated with both AMD (7-13) and aHUS (5,6), where in some cases they have been
shown to affect the interaction of CFH with GAGs (12,20,23,25). For example, the Y402H
polymorphism of CFH (26), a major risk factor for AMD (7-10,27), alters its binding to the
GAGs heparin, heparan sulfate (HS) and dermatan sulfate (DS) (12,20,23) through a
tyrosine to histidine substitution at residue 402 within CCP7.
Functional changes within the CFH protein, caused by mutations/polymorphisms, could
alter its ability to bind host surfaces. The current understanding is that CCPs19-20 are
chiefly responsible for host-recognition (28), which is consistent with the large number of
polymorphisms/mutations in this region associated with aHUS (5,6). However, with the
exception of R1210C (13), mutations/polymorphisms in CCPs19-20 are not associated with
an increased risk of developing AMD, and the Y402H polymorphism has no effect on the
susceptibility of an individual to develop aHUS. We found previously that the Y402H
polymorphism had a significant effect on the binding specificity of CFH for sulfated GAGs
(20,23) and that the 402H form of CFH bound less well to the Bruch’s membrane of human
macula, where this interaction was mediated, at least in part, by the GAGs HS and DS (12).
Poorer binding of the AMD-associated 402H variant to this ECM could lead to reduced
complement regulation at this site resulting in chronic local inflammation and thereby
promoting the tissue damage and drusen formation that characterize AMD (3,4,12). On this
basis we have hypothesized that the two GAG-binding sites have tissue-specific activities,
potentially via their recognition of different HS structures. In order to test this hypothesis we
have compared the GAG-binding specificities of CCP6-8 and CCP19-20 and have
investigated their relative contributions to the interactions of CFH with human eye and
kidney tissues.
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Materials and Methods
Expression of complement factor H reagents
The 402H and 402Y polymorphic variants of flCFH were purified from the plasma of
genotyped donors who were homozygous for either allele, as described in (29); these
preparations each had isoleucine at position 62. Recombinant proteins representing the 402H
and 402Y variants of CFH and comprising CCPs6-8 were expressed in E. coli, refolded and
purified as described previously (20). A recombinant protein comprising CCPs19-20 of CFH
(designated as residues 1107 to 1231 in the published CFH sequence, UniProt no. P08603)
was expressed in P. pastoris as described previously (21); this recombinant protein sequence
also includes the non-authentic tetrapeptide EAEF at the N-terminus. All of the recombinant
proteins (which come from non-glycosylated regions of CFH (17)) have been shown
previously to be correctly folded (20,21,23).
Fluorescent labeling and biotinylation of proteins and GAG reagents
The fluorescent labeling of the 402H and 402Y variants of CFH (both CCP6-8 and full-
length proteins) with AlexaFluor594 and AlexaFluor488, respectively, was done as
described previously (12). Labeling of the CCP19-20 recombinant protein with
AlexaFluor488 was carried out in an identical manner, using the same protein labeling kit
(Molecular Probes, Paisley, UK) in the presence of 10-fold molar excess of heparin dp24
oligosaccharide (Iduron, Manchester, UK) in order to protect the GAG-binding site. The
heparin dp24 was removed from the labeled CCP19-20 protein by exhaustive dialysis
against PBS supplemented with 1 M NaCl using 10-kDa molecular weight cut-off snakeskin
dialysis tubing (Pierce, Cramlington, UK) in the dark at 4°C, as described previously (12).
The labeling efficiency was calculated to be 1.5 moles fluorophore per mole of protein (the
same degree of labeling as for the CCP6-8 proteins (12)). Labeling of the CCP19-20 protein
was shown to have no major effect on its heparin binding properties by affinity
chromatography (data not shown). Biotinylation of the CCP6-8 and CCP19-20 recombinant
proteins, also performed in the presence of 10-fold molar excess heparin dp24
oligosaccharide (Iduron) to protect the GAG-binding region, was carried out using the same
methodology as employed previously (20).
Biotinylation of the 2nd international standard (2IS) of heparin (30), C4S, C6S and DS were
carried out as described in Clark et al. 2006 (20). Biotinylation of hyaluronan (HA) was
carried out essentially as described previously (31). Briefly, medical grade HA (Lifecore
Biomedical, Chaska, USA) was dissolved overnight in 0.1 M MES, pH5.5 at a concentration
of 5 mg/ml. To 1 ml of this solution 13 μl of 25 mg/ml 1-ethyl-3-(3-
dimethylaminopropyl)carbo-dimide hydrochloride (EDAC: Sigma, Poole, UK) in 0.1 M
MES, pH 6.5, and 20μl of 50mM Biotin-LC-hydrazide (Pierce) in DMSO, were added
simultaneously and mixed at room temperature for 16 hours. The sample was then
centrifuged at ~12,000 g for 1 min to remove particulate material and the reaction mixture
was dialyzed into H2O at 4 °C for 6 hours using 10,000 Da molecular weight cut-off
snakeskin dialysis tubing (Pierce).
Microtiter plate assays
The heparin-binding characteristics of the biotinylated CCP6-8 (402H and 402Y variants)
and CCP19-20 recombinant proteins was analyzed using microtiter plate based assays,
where 2IS (2nd International Standard) heparin (20), or one of its selectively desulfated
derivatives (32,33), were immobilized non-covalently on allylamine-coated BD Heparin
Binding plates (BD Biosciences, Oxford, UK) as we have described previously (20,34). The
selectively desulfated samples of the 2IS heparin used in this study were: 2-O desulfated (2-
O-deS); 6-O desulfated (6-O-deS); 2- and 6-O desulfated (2,6-O-deS); N-desulfated (N-deS)
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and N-desulfated re-N-acetylated (N-deS/re-N-Ac). The GAGs were immobilized at 1 μg/
well on BD Heparin Binding plates in a total volume of 200 μl/well PBS, overnight at room
temperature. Plates were blocked for 90 minutes at 37 °C with 300 μl/well 1% (w/v) BSA in
standard assay buffer (20 mM HEPES, 130 mM NaCl, 0.05% (v/v) Tween-20, pH 7.3). This
standard assay buffer was used for all subsequent incubations, dilutions and washes at room
temperature. Biotinylated recombinant protein was incubated with the immobilized GAGs
for 4 hours at room temperature. After the plates were washed bound protein was detected
by the addition of 200 μl/well of a 1:10,000 dilution of ExtrAvidin alkaline phosphatase
(Sigma-Aldrich, Poole, UK) for 30 minutes at room temperature. After further washing,
plates were developed using 200 μl/well of a 1 mg/ml disodium p-nitrophenylphosphate
solution (Sigma-Aldrich) in 0.05 M Tris-HCl, 0.1 M NaCl, pH 9.3. The absorbance values at
405 nm were determined after 40 minutes of development at room temperature and
corrected against blank wells (i.e., those that contained no immobilised GAGs).
Alternatively, unlabelled CCP6-8 (either the 402H or 402Y variant) or CCP19-20
recombinant proteins were adsorbed onto the wells of microtitre plates (Nunc Maxisorb,
Kastrup, Denmark) at 1 μg/ml in 200 μl PBS for 16 hours at 4 °C. The ligand-binding
characteristics of these immobilized proteins were determined using the biotinylated GAGs
2IS heparin, hyaluronan, C4S, C6S and DS. Plate assays were carried out in 20 mM HEPES,
130 mM NaCl, 0.05 % (v/v) Tween-20, pH 7.3 and the level of bound GAG determined as
described above for the biotinylated proteins. In all these plate assays, data points were
determined in duplicate and are reported as a n=4 from two independent experiments.
Fluorescent staining of human eye and kidney tissue with flCFH
Details of the human eye and kidney tissues (without AMD or kidney disease, respectively)
used in this study are provided in Table 1. The staining of human tissue sections with
fluorescently labeled proteins was carried out as described previously (12). Briefly, tissue
sections were incubated with chilled (−20°C) histological grade acetone (Sigma-Aldrich) for
twenty seconds before being thoroughly washed with PBS: every step of the protocol was
preceded by a wash step, each time in PBS alone. These were then blocked with 1 mg/ml
BSA, 1% (v/v) goat serum, 0.1% (v/v) Triton X-100 in PBS for 1 h at room temperature.
Tissue sections were incubated with the fluorescently labelled variants of flCFH, CCP6-8 or
recombinant CCP19-20 (20 μg/ml of each in 100 μl blocking buffer) for 16 h at 4°C:
‘blank’ (i.e. non-stained) tissue sections were incubated with blocking buffer alone. Cell
nuclei were visualized using DAPI (0.3 μM final concentration) for 5 min at room
temperature. Microscope cover slips were mounted using VectaShield (VectorLabs,
Peterborough, UK). Endogenous expression of CFH was visualized using the anti-CFH
monoclonal antibody OX23 (35) at 10 μg/ml in blocking buffer. OX23 was incubated with
tissue sections for 16 h at 4°C, washed with PBS and detected using AlexaFluor 488-
conjugated goat anti-mouse IgG (Molecular Probes) at a 1:5000 dilution in PBS for 2 h at
room temperature.
In competition experiments, the labeled variants of flCFH (either 402H or 402Y) were
added to tissue sections in the presence of either a 1-fold or 10-fold molar excess of
unlabeled CCP6-8 (i.e. the respective 402H and 402Y variant) and/or CCP19-20. In other
experiments, kidney tissue was pre-treated with specific HS/DS-degrading enzymes (i.e. a
mixture of heparinase I, II and III and chondroitin B lyase, all from Flavobacterium
heparinum (36,37)) before the application of either fluorescently labeled flCFH variant
proteins or the anti-CFH antibody OX23; 20 units/ml of each enzyme (Sigma-Aldrich) was
incubated with the tissue sections for 2 hours at 37°C followed by thorough washing with
PBS before blocking.
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Fluorescent microscopy and data analysis
Images of fluorescently stained human tissue were collected on a snapshot widefield
microscope (Olympus BX51) using a 20x/0.30 Plan Fln objective. Microscopy images were
captured using a CoolSNAP ES camera (Photo-metrics) via MetaVue Software (Molecular
Devices). In order to prevent bleed-through of color from one channel to the next, specific
band pass filter sets were used for DAPI, FITC and Texas Red. All images were processed
and analyzed using ImageJ64 (version 1.40g; rsb.info.nih.gov/ij). Relative fluorescent
intensities (i.e. of RPE and Bruch’s membrane in the eye samples and glomeruli in the
kidney samples) were determined as described previously (12). In the case of human kidney
tissues, the freehand tool (in ImageJ64) was used to select ten individual glomeruli
(designated in this study as the tissue within the Bowman’s space) from each donor; the ten,
mean fluorescence intensity values were then averaged per donor in order to compensate for
varying blood vessel number per glomeruli. For both eye and kidney tissues, the gray scale
images for the red and green channels were overlaid so that an identical region was
compared for both wavelengths. Tissue sections from five donor eyes and three donor
kidneys were analyzed to obtain mean values (± s.e.m.) and the statistical significance of
protein binding determined using Student’s t test (in KaleidaGraph v4.0), where P<0.05 was
considered to be significant.
Heparin affinity chromatography.
The heparin-binding properties of the CCP19-20 region of CFH was compared to the 402H
and 402Y variants of both flCFH and the CCP6-8 region of CFH by affinity
chromatography on a 1 ml HiTrap Heparin column (GE Healthcare, Buckinghamshire, UK)
at room temperature. The column was equilibrated in 5 ml PBS (OXOID). Protein (100 μg
recombinant CCP6-8/CCP19-20 proteins or 200 μg flCFH) was loaded onto the column in a
total volume of 5 ml PBS. The column was then washed with 4 column volumes of PBS
before bound protein was eluted with a linear salt gradient (over 20 m) of 0-100% buffer A
(1 M NaCl in PBS) in PBS at a flow rate of 1 ml/min; fractions (1 ml) were collected
throughout the protocol.
Results
CCP6-8 and CCP19-20 regions of CFH have different GAG-binding characteristics
We examined the binding of the CCP6-8 and CCP19-20 regions of CFH to the GAG
heparin, a highly sulfated form of HS often used as a model for the HS found ubiquitously in
human tissues; both GAGs exhibit a diverse range of sequences (see Supplemental Fig 1)
(3,38). Affinity chromatography using a HiTrap heparin column revealed that recombinant
CCP19-20 protein eluted at a lower salt strength when compared to the 402H and 402Y
variants, either in the context of a CCP6-8 construct or full-length CFH protein (flCFH)
purified from homozygous individuals (Fig. 1). Thus the CCP19-20 region has the weakest
(salt-dependent) binding to heparin. However, it was apparent that flCFH demonstrated
better binding to heparin than either CCP6-8 or CCP19-20. This indicates that both of these
regions contribute to the strong binding of flCFH to heparin, which is consistent with a
recent study (39). Consistent with the above, the CCP19-20 construct demonstrated poorer
binding to heparin compared to CCP6-8 in microtiter plate assays, where these experiments
were conducted in physiological buffer conditions (Supplemental Fig. 2A). Similar analyses
with other GAGs indicated that CCP19-20 does not interact significantly with chondroitin-4-
sulfate (C4S), chondroitin-6-sulfate (C6S), DS or hyaluronan (HA) (Supplemental Fig. 2B-
E); of these GAGs only DS has been found previously to interact with CCP6-8 (12,20) and
very weak binding has been reported for CCP19-20 with C6S (25).
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Given the diversity of heparin/HS sequences (e.g. their wide range of sulfation patterns) we
investigated the specificity of CCP19-20 (Fig. 2) in order to compare this with those of the
402H and 402Y CCP6-8 variants, which we have analyzed previously (20,23); as before,
this utilized selectively desulfated derivatives of heparin (32,33) as models of HS. All the
partially desulfated preparations of heparin demonstrated poorer binding to CCP19-20 than
to the unmodified GAG (Fig. 2) demonstrating that the sulfate groups play a key role in this
interaction. From these data it might be anticipated that highly sulfated forms of HS would
be required for optimal binding to the CCP19-20 region of CFH. Thus, the sulfate specificity
of the CCP19-20 region is similar to the 402H variant, in that this form of CCP6-8 was more
sensitive to removal of sulfate groups compared to 402Y (20,23); the control data for the
CCP6-8 402H and 402Y proteins has been included here for completeness and ease of
comparison (Supplemental Fig. 3), where these were essentially the same as those obtained
previously (20,23).
However, the specificities of CCP19-20 (Fig. 2) and CCP6-8 402H (Supplemental Fig. 3B)
although similar are not identical; e.g. N-desulfation/re-N-acetylation of heparin has a
smaller effect on CCP19-20 binding compared to the 402H variant while the converse is
seen for removal of 6-O-sulfates. On this basis CCPs19-20 would be expected to recognize
different HS sequences compared to CCPs6-8, which may affect the way CFH recognizes
HS in human tissues.
CCPs6-8 contribute more than CCPs19-20 to CFH binding to sites in human macula
Having demonstrated that the heparin-binding strengths/specificities of the CCP6-8 and
CCP19-20 regions differed from one another in experiments using purified GAG
preparations, we investigated their relative contributions to binding-site recognition in
human tissues. Unlabeled CCP6-8 and CCP19-20 proteins were used as competitive
inhibitors for the interaction of fluorescently labeled flCFH (i.e. 402H or 402Y) with human
macula tissues from non-AMD donors (age range 58-81 years; Table 1), using a
modification of the method described previously (12). CCPs19-20 caused little or no
inhibition of flCFH binding to the RPE or Bruch’s membrane even at 10-fold molar excess
(Fig. 3A); statistically significant effects were only seen for competition of the 402Y variant
corresponding to ~11% and ~20% reduction in binding to the RPE and Bruch’s membrane,
respectively. However, when an equivalent experiment was performed with CCP6-8 a large
and statistically significant decrease in binding of flCFH was observed on both RPE and
Bruch’s membrane (Fig. 3B); e.g. with 10-fold molar excess of CCP6-8 there was 77%
inhibition of flCFH binding to the Bruch’s membrane for the 402H variant. These data
clearly demonstrate that CCPs6-8 make a larger contribution to binding of CFH than
CCPs19-20. When the CCP6-8 and CCP19-20 proteins were used together as competitors
this lead to a greater level of inhibition (Fig. 3C) than that seen for CCP6-8 alone (Fig. 3B).
The enhanced competition could be explained by CCPs6-8 and CCPs19-20 recognizing
distinct HS structures within human macula. Overall, these results demonstrate that CCPs6-8
play a more prominent role in the interaction of CFH with human macula, although
CCPs19-20 likely makes some contribution to binding in the context of the full-length CFH.
Tissue binding experiments revealed that fluorescently labeled CCP19-20 was able to bind
directly to the Bruch’s membrane (albeit weakly) and to the RPE (Fig. 4). The pattern of
binding for CCP19-20 was similar to that for the 402H variant of CCP6-8, both of which
bound less well to the Bruch’s membrane compared to the 402Y form of CCP6-8; all three
constructs exhibited essentially identical levels of binding to the RPE (Fig. 4C-D). This may
be because CCP19-20 and CCP6-8 402H require highly sulfated HS structures for optimal
binding (based on the specificities described in Fig. 2 and Supplemental Fig. 3B), of which
there may be relatively few in Bruch’s membrane; the broader specificity of 402Y ((20,23);
and Supplemental Fig. 3A) would allow it to interact with a wide range of HS sequences
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within this specialized ECM. Enzyme pretreatment of human eye sections to remove HS
caused a small but significant reduction (~20%) in binding of CCP19-20 to the RPE, that
was not further reduced by the additional removal of DS (Fig. 5). In the case of the Bruch’s
membrane there was a 55% reduction in the binding of CCP19-20 when HS alone or DS/HS
together were removed. This demonstrates that the CCP19-20 region of CFH recognizes HS
(but not DS) in human macula (consistent with the GAG specificity described above).
However, the effect of enzyme digestion was much less marked on CCP19-20 binding
compared to CCP6-8, where removal of DS/HS reduced binding by ≥90% (12), indicating
that CCPs19-20 also recognize non-GAG ligands; staining with an anti-C3b antibody
showed that there was little or no C3b in either the macula or kidney donor tissues used
within this study (see Supplemental Fig. 4), indicating that C3b is unlikely to be responsible
for the GAG-independent binding seen here for CFH. The results described above
demonstrate that CCP6-8 has a greater role than CCP19-20 in mediating the interaction of
CFH with sites in human macula, which is in agreement with previous data showing that
flCFH and CCP6-8 have similar patterns of binding on Bruch’s membrane, RPE and
choroidal blood vessels (12).
Binding of CFH to human kidney glomeruli is mediated by the CCP19-20 region
Given the different HS-binding specificities of the CCP6-8 and CCP19-20 regions (see
above), and that different tissues have HS with distinct compositions and sulfation patterns
(3,38,40), we investigated whether the relative contributions of these GAG-binding regions
was the same in human kidney; this tissue was chosen because of the association of
mutations/polymorphisms in CCPs19-20 with aHUS (5,6). Staining with an anti-CFH
antibody showed that the endogenous CFH protein is present throughout the glomerulus,
being particularly prominent on the Bowman’s capsule and glomerular basement membrane
(GBM) (Fig. 6A). A similar staining pattern was apparent when fluorescently labeled
CCP19-20 was used as a probe to detect its binding sites (Fig. 6B), whereas, neither the
402H nor 402Y variants of CCP6-8 bound significantly to this tissue (Fig. 6C). This
observation suggests that the CCP19-20 region plays a more prominent role in the binding
of CFH to human glomeruli compared to CCP6-8. When kidney tissue was stained with
fluorescently labeled flCFH proteins both the 402H and 402Y variants bound to similar
degrees throughout most of the glomerulus but with somewhat greater binding to the GBM
(orange/yellow staining in Fig. 6D); the exception to this was the Bowman’s capsule, where
there was a higher level of 402Y flCFH (green) staining. Pre-treatment of the kidney tissue
with GAG-degrading enzymes lead to a ~30-40% reduction in the fluorescence intensity
observed in the glomeruli with the labeled 402H and 402Y flCFH variants (Fig. 7A) and an
~60% reduction in CCP19-20 binding (Fig. 7B). These data indicate a likely role for HS in
the binding of CFH to the glomeruli of human kidneys. However, the relatively small effect
of GAG removal on CCP19-20 binding in the kidney (compared to >90% reduction of
CCP6-8 binding in the macula (12)) provides evidence that CCP19-20 also interacts with
non-GAG ligands in this tissue.
To further assess the relative contributions of CCPs6-8 and CCPs19-20 on CFH binding to
human kidney we performed competition experiments, essentially as described above for
eye tissue. The CCP6-8 variant proteins caused no statistically significant inhibition of
flCFH binding (Fig. 8B), whereas, the CCP19-20 protein caused ~60% inhibition when
present at 10-fold molar excess (Fig. 8A). Competition of flCFH binding, using CCP6-8 and
CC19-20 together, had no greater effect than CCP19-20 alone (Fig. 8C). Overall, these data
demonstrate that, in contrast to human macula, CCPs19-20 play the dominant role in the
binding of CFH to sites within human kidney glomeruli, and that, at least in part, this is via
its interaction with HS.
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Discussion
Here, we demonstrate that the two GAG-binding regions of CFH both play a major role in
the localization of the protein on host surfaces, but that the relative contribution of these
regions is tissue-specific; CCPs6-8 predominate in CFH binding to the human RPE and
Bruch’s membrane, whereas CCPs19-20 mediate the interaction with human kidney
glomeruli. These data correlate well with the evidence that the Y402H polymorphism (in
CCP7) is associated with AMD (7-10,27), while mutations/polymorphisms in CCPs19-20
are associated with kidney diseases such as aHUS (5,6). Interestingly, we have also found
that the mechanism underlying the tissue binding of the CCP6-8 and CCP19-20 regions
differ, in that the former is mediated primarily via its interaction with sulfated GAGs,
whereas a significant component of the latter is GAG-independent. Hence, while digestion
of HS/DS reduces the binding of CCP6-8 by ≥90% in Bruch’s membrane (12), removal of
these GAGs leads to only a ~50% reduction in the binding of CCP19-20 to both Bruch’s
membrane and kidney tissue. However, from our analyses it is clear that ~50% of CCP19-20
binding, to sites in these tissues, is mediated through its interaction with HS. In this regard,
while the GAG-binding specificity of CCP19-20 was shown to differ from that of CCP6-8 in
the details of their sulfation requirements, it was more similar to the 402H variant (compared
to 402Y) in that it bound best to highly sulfated forms of heparin. Overall these data suggest
that the Bruch’s membrane contains only a relatively small number of appropriately sulfated
HS sequences that are able to support the binding of CCP19-20 and the 402H form of
CCP6-8. Furthermore, the results of our competition experiments indicate that CCPs6-8 and
CCPs19-20 recognize different HS structures in the human eye, allowing high avidity
interaction of the full-length CFH protein by the utilization of two independent binding sites
(i.e. even in the context of the 402H isoform of CFH).
Both AMD and aHUS are conditions thought to result from complement dysregulation
brought about, at least in part, by abnormalities in CFH binding/function (6,11,12,41). The
results we described here provide evidence that polymorphisms/mutations in different
regions of CFH differentially affect its activity in different tissues and thus predispose to
different diseases. Consistent with this, the common Y402H polymorphism is associated
with AMD and not aHUS, whereas the majority of amino acid substitutions in CCPs19-20
associated with aHUS have not been linked to AMD (5,6). One exception to this is the
highly penetrant, but rare, R1210C mutation in the C-terminal region of CCP20 that confers
high risk of developing AMD (13). While the effects of this mutation on GAG binding have
not been tested in the context of the full-length protein, it does affect the binding of
CCPs8-20 to heparin (42,43), and also has a major effect on the interaction of CFH with
surface bound C3b (44). Importantly, the R1210C mutant of CFH has also been shown to
form a high molecular weight covalent complex with human serum albumin (44), which
would have a dramatic effect on the movement of CFH through the Bruch’s membrane (45)
as well as masking/altering other functions (44). Thus, the association of R1210C with
AMD may be independent of any effect on GAG binding. It should be noted that 60% of
individuals who carry the R1210C CFH allele and have AMD also have a 402H CFH allele
(13). Based on our description of the importance of CCPs6-8 in the interaction of CFH with
sites in normal macula and the effect of the Y402H polymorphism on GAG binding (12,20),
the impaired R1210C function would not be compensated well by the CFH 402H produced
from the other allele in these patients.
Another recent study has shown that a major CFH ligand is malondialdehyde (MDA), a
common lipid peroxidation product found to accumulate in diseases such as AMD as a result
of oxidative stress (46); e.g. MDA is found on the surface of apoptotic/necrotic cells and
blebs derived from these. Importantly, it was demonstrated that CFH binds to MDA via both
CCPs 7 and 20, and that the Y402H polymorphism dramatically reduced binding.
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Furthermore, it has been proposed that MDA-mediated CFH recruitment inhibits
complement activation in regions with drusen build-up and that reduced binding of the 402H
CFH variant would be pro-inflammatory (46). Thus, whilst the impaired binding of 402H to
Bruch’s membrane could result in local complement dysregulation contributing to disease
initiation, as we have suggested previously (4,12), it could also be the case that the altered
binding to ligands such as CRP (47-49), necrotic cells (46,47) and oxidized lipids (46),
could be important in driving AMD progression once drusen have started to form. Both the
work described here and that from Weisman and colleagues (46) provides strong evidence
that the Y402H polymorphism within the CCP6-8 region of CFH plays a major role in AMD
pathogenesis because of the direct effect that this has on its binding functions.
A major finding of our study is that the CCP6-8 and CCP19-20 regions of CFH
differentially mediate binding in different host tissues, which occurs, at least in part, through
their recognition of distinct GAG populations. It is well established that GAG composition/
sequence is dependent on tissue location (3,38) and, for example, even within the different
layers of the macula there is evidence for considerable diversity of GAG structure (40). In
this regard, the 402H and 402Y variants (in the context of CCPs6-8) recognize different
GAG sequences in human Bruch’s membrane (12) and the current study demonstrates that
the specificity of CCPs19-20 for HS in this ECM is different again. As noted above, the
profound effect of the Y402H polymorphism on GAG binding could explain the functional
basis of this polymorphism in AMD. On the other hand, the interaction of CCPs19-20 with
HS clearly mediates a significant proportion of CFH binding to kidney GBM. Consistent
with this, expression of glomerular heparinase has been shown to increase in patients
suffering from dense deposit disease (another kidney condition associated with CFH
polymorphisms/mutations in CCP19-20), where the staining of HS in the GBM decreases
accordingly (50).
Given the importance of correct surface recognition by CFH on complement regulation, it is
not surprising that disruption of this event can result in diseases such as AMD and aHUS.
The current widely held view that one main surface-recognition region exists in CFH, and
that this resides in the CCP19-20 portion of the protein, may be simplistic and, in the case of
certain tissues such as the human macula, incorrect. Knowledge that the contribution to host
surveillance conferred by the two GAG-binding regions of CFH alters depending on the
tissue context should permit organ-specific therapeutic strategies to re-address the balance of
immune regulation in AMD and other diseases of complement dysregulation.
Supplementary Material
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Figure 1. CCP19-20 binds poorly to heparin compared to CCP6-8
Recombinant CCP19-20 (blue), and the 402H (red) and 402Y (green) variants of CCP6-8
(solid lines) and flCFH (dotted lines) were analyzed using heparin affinity chromatography.
The proteins were eluted using a NaCl gradient (conductivity denoted by brown dashed line)
where the absorbance was monitored at 280 nm; these data are representative of at least two
independent experiments. The differential (salt-dependent) binding strength of the 402H and
402Y CCP6-8 variants is consistent with our previous results on a HiTrap Heparin column
(12, 20). The lack of differential binding between the 402H and 402Y forms of flCFH is
likely to be due to the highly sulfated nature of the heparin used here and the consequent
lack of resolution of the column when two binding sites (CCP6-8 and CCP19-20) are both
contributing to the avidity.
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Figure 2. Sulfate groups of heparin play a major role in CCP19-20 binding
The interaction of biotinylated CCP19-20 with immobilized heparin preparations was
determined using the microtiter plate assay described before (20); heparin was either
untreated (2IS: ●) or had been selectively desulfated: 2-O-desulfated (□); 6-O-desulfated
(△); 2,6-O-desulfated (◇); N-desulfated (▽); N-desulfated re-N-acetylated (○). All values
are plotted as mean absorbance (at 405 nm) determined from two independent experiments
(n=4) ± s.e.m. The CCP6-8 402H and 402Y variants were used as controls in these
experiments (Supplemental Fig.3) and gave essentially identical results to those published
previously (20,23).
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Figure 3. CCP6-8 contributes more than CCP19-20 to flCFH binding in macula tissue
The 402H and 402Y forms of flCFH (fluorescently labeled with AlexaFluor594 and
AlexaFluor488, respectively) were incubated with human tissue sections in the absence or in
the presence of 1- or 10-fold molar excess CCP19-20 (A) or CCP6-8 (B) or CCP6-8 and
CCP19-20 together (C); in (B) and (C) matching allotypes of CCP6-8 and flCFH were used
(i.e. either 402H vs 402H or 402Y vs 402Y). In each case, the relative fluorescence was
measured for the RPE and Bruch’s membrane from five different donors after subtracting
autofluorescence from blanks, and the data are plotted as percentage binding for flCFH in
the absence of competitor ± s.e.m. Data were analyzed (compared to non-competed) using a
paired Student’s t test where P<0.05 was considered to represent a significant difference; * =
P<0.05 and ** = P<0.001.
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Figure 4. Comparison of CCP19-20 and CCP6-8 binding sites in the RPE and Bruch’s
membrane of human macula tissue
(A) CCP19-20 (green) and (B) CCP6-8 (402H (red) and 402Y (green)) were exogenously
applied to human macula tissue in order to detect their binding sites within RPE and Bruch’s
membrane (BM). In (B) the 402H and 402Y forms of CCP6-8 were added simultaneously
giving rise to yellow/orange staining at sites where they bind equivalently. The relative
fluorescence values measured for each protein was averaged over all 5 donors (as listed in
Table 1) where the autofluorescence from blanks had been subtracted for each donor. Data
are compared for the RPE (C) and Bruch’s membrane (D) and are shown as mean value ±
s.e.m. Images in (A) and (B) are from donor M12109 (Table 1) and are representative of the
5 individual donors analyzed; cell nuclei are stained with DAPI (blue) and scale bars
correspond to 10 μm.
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Fig. 5. Role of GAGs in the binding of CCP19-20 to human macula
The binding of fluorescently labeled CCP19-20 to RPE and Bruch’s membrane was
measured following enzymatic pre-treatments with a mixture of heparinase I, II, III in the
absence or presence of chondroinitase B, i.e. to remove either HS alone or DS/HS together.
Data from 5 donor eyes (see Table 1) were averaged and plotted as the percentage of
binding seen for CCP19-20 in the absence of enzyme pre-treatment ± s.e.m. Data were
analyzed using a paired Student’s t test where P<0.05 was considered to represent a
significant difference; * = P<0.05 and ** = P<0.001.
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Figure 6. Localization of endogenous CFH and CFH-, CCP6-8- and CCP19-20-binding sites in
human kidney
(A) Endogenously expressed CFH was detected in the glomeruli of human kidney using the
OX23 antibody (green); particularly intense staining was seen within the Bowman’s capsule
(solid arrows) and, to a lesser extent, for the GBM (open arrows). (B) CCP19-20-binding
sites were detected with fluorescently labeled CCP19-20 (green). (C) CCP6-8-binding sites
were stained for with fluorescently labeled 402H (red) and 402Y (green) variants of CPP6-8.
(D) CFH-binding sites were visualized using fluorescently labeled 402H (red) and 402Y
(green) variants of flCFH that were exogenously applied to the kidney tissue (the Bowman’s
capsule is indicated by a solid arrow). All images are from donor NHK9 (Table 1) and are
representative of the three separate kidney donors analyzed; cell nuclei are stained with
DAPI (blue) and scale bars correspond to 100 μm.
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Figure 7. Role of GAGs in the binding of CFH to glomeruli
The binding of fluorescently labelled 402H and 402Y variants of flCFH (A) or fluorescently
labelled CCP19-20 (B) to sites within the glomeruli of human kidneys was determined with
and without enzymatic pre-treatments (a mixture of heparinase I, II, III and chondroinitase
B), i.e. to remove both HS and DS. Data for 10 entire glomeruli from each of three donors
(see Table 1) were averaged and plotted as the percentage of binding seen for the respective
CFH proteins in the absence of enzyme pre-treatment ± s.e.m. Data were analyzed using a
paired Student’s t test where P<0.05 (*) was considered to represent a significant difference.
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Figure 8. CP19-20 contributes more to the binding of flCFH to human kidney glomeruli than
CCP6-8
The 402H (grey bars) and 402Y (white bars) variants of flCFH were incubated with human
kidney tissue sections in the absence or presence of 1- or 10-fold molar excess CCP19-20
(A), CCP6-8 (B) or CCP6-8 and CCP19-20 together (C); in (B) matching allotypes of
CCP6-8 and flCFH were used (i.e. either 402H vs 402H or 402Y vs 402Y). In each case the
relative fluorescence of the whole glomeruli (designated here as tissue within the Bowman’s
space) was measured and the data plotted as a percentage binding compared to non-
competed flCFH: mean data are plotted for each of three donor samples (each averaged from
10 glomeruli) ± s.e.m. Statistical analysis was performed using a paired Student’s t test,
where P<0.05 was considered to be significant; * = P<0.05.
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Table 1
Details of the donor tissue used in binding experiments.
Human eye tissue *
Donor no. Sex Age Days Post Mortem †
M12103 F 82 1
M12107 M 81 1
M12109 F 70 1
M12189 M 64 2
M12190 M 58 2
Human kidney tissue ‡
RW1 F 54 N/A§
NHK6 M 37 N/A§
NHK9 M 49 N/A§
*All human eye samples used in this study are from genotyped individuals who were CFH 402 H/Y heterozygotes and who did not have AMD.
†
The number of days macula were collected and fixed after death.
‡
Human kidney tissue was from donors without aHUS or other kidney disease.
§
These samples were excised from unused donor kidneys perfused with transplant solution and that had been kept on ice.
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